bluebird bio Inc - ESG Rating & Company Profile powered by AI
This page displays a zero-cost Sustainability analysis for bluebird bio Inc. The SDG rating for bluebird bio Inc represents the company's reporting of the United Nations Sustainable Development Goals. Alternative companies in the rating industry group for bluebird bio Inc are displayed below.
bluebird bio Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 6.7; made up of an environmental score of 6.4, social score of 4.8 and governance score of 8.0.
6.7
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Novartis AG | 9.2 | High |
| 2 | Daiichi Sankyo Co Ltd | 8.9 | High |
| 432 | Twist Bioscience Corp | 6.8 | High |
| 432 | Rhythm Pharmaceuticals Inc | 6.8 | High |
| 446 | bluebird bio Inc | 6.7 | High |
| 446 | Actinium Pharmaceuticals Inc | 6.7 | High |
| 446 | AnGes Inc | 6.7 | High |
| ... | ... | ... | |
| 2749 | Xynomic Pharmaceuticals Holdings Inc | 0.0 | Low |
| 2749 | Zyden Gentec Ltd | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does bluebird bio Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes bluebird bio Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes bluebird bio Inc report the average age of the workforce?
Sign up for free to unlockDoes bluebird bio Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes bluebird bio Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes bluebird bio Inc disclose cybersecurity risks?
Sign up for free to unlockDoes bluebird bio Inc offer flexible work?
Sign up for free to unlockDoes bluebird bio Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes bluebird bio Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes bluebird bio Inc conduct supply chain audits?
Sign up for free to unlockDoes bluebird bio Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes bluebird bio Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes bluebird bio Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes bluebird bio Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes bluebird bio Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes bluebird bio Inc disclose water use targets?
Sign up for free to unlockDoes bluebird bio Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid bluebird bio Inc have a product recall in the last two years?
Sign up for free to unlockDoes bluebird bio Inc disclose incidents of discrimination?
Sign up for free to unlockDoes bluebird bio Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas bluebird bio Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes bluebird bio Inc disclose parental leave metrics?
Sign up for free to unlockDoes bluebird bio Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes bluebird bio Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes bluebird bio Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes bluebird bio Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes bluebird bio Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes bluebird bio Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs bluebird bio Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes bluebird bio Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes bluebird bio Inc disclose its waste policy?
Sign up for free to unlockDoes bluebird bio Inc report according to TCFD requirements?
Sign up for free to unlockDoes bluebird bio Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes bluebird bio Inc disclose energy use targets?
Sign up for free to unlockDoes bluebird bio Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes bluebird bio Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for bluebird bio Inc
These potential risks are based on the size, segment and geographies of the company.
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company's clinical study program includes HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has strategic collaboration and license agreements with Orchard Therapeutics Limited, Forty Seven, Inc., and Magenta Therapeutics, Inc. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Cambridge, Massachusetts.